PIGMENTATION DISORDERS TREATMENT MARKET ANALYSIS

Key Developments

• In September, 2023, Almirall, S.A, a pharmaceutical company, announced the launch of its atopic dermatitis (AD) awareness campaign “Moving AheAD” in observance of World Atopic Eczema Day. The aim of the campaign is to bring new initiatives and strategies to increase awareness among society, patients, and healthcare professionals.
• In November 2022, Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that it had entered into a license agreement with Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company. Under this agreement, Aclaris Therapeutics, Inc. granted Pediatrix exclusive rights to develop, manufacture, and commercialize ATI-1777, for diseases including atopic dermatitis, vitiligo, and others, in Greater China.
• In October 2022, Incyte, a U.S-based multinational pharmaceutical company, announced that it had acquired Villaris Therapeutics, Inc., a biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo. According to the terms of the agreement, Incyte will acquire Villaris and the exclusive global rights to develop and commercialize auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody, for all uses including in vitiligo and other autoimmune and inflammatory diseases
• In July, 2022, Incyte announced that it had received an approval from the U.S. Food and drug Administration, for Opzelura (Ruxolitinib) Cream indicated for the treatment of vitiligo
• In June 2022, Ahammune Biosciences Pvt. Ltd., an innovation-led drug discovery company, and Veeda Clinical Research, a provider of end-to-end drug development services, entered into a partnership for first in human studies with Ahammune’s investigational new drug- AB1001, being developed as a topical therapy for vitiligo